GlassScriptPhysician profile
Anthony T Johnson
NPI 1912918772
$6,567.53
in general payments reported to CMS, 2019-2025
32 companies · $957 in 2025
The $957 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $760 · 2021: $525 · 2022: $1,066 · 2023: $982 · 2024: $1,260 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199 · Education: $0.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,199.01 |
| Education | $0.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,261.88 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $984.06 | 2021-2025 | |
| Lilly USA, LLC | $904.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $322.11 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $306.17 | 2019-2024 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.95 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $250.71 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $238.76 | 2020-2025 | |
| Pfizer INC. | $238.25 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.93 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $207.98 | 2019-2024 | Nucala |
| Allergan, INC. | $193.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $186.65 | 2020-2025 | Vaxneuvance, Gardasil 9, Verquvo |
| Janssen Pharmaceuticals, INC | $171.72 | 2019-2023 | Spravato |
| Dexcom, INC. | $137.35 | 2021-2024 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $85.36 | 2019-2022 | |
| Daiichi Sankyo INC. | $79.88 | 2022-2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $78.95 | 2020-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $72.46 | 2024-2025 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $55.09 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $54.82 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $45.30 | 2022 | |
| Xeris Pharmaceuticals, INC. | $32.03 | 2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $32.02 | 2025 | |
| Exact Sciences Corporation | $31.40 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.50 | 2025 | Caplyta |
| Madrigal Pharmaceuticals | $20.66 | 2025 | Rezdiffra |
| Axsome Therapeutics, INC. | $15.76 | 2024 | Auvelity |
| Lexicon Pharmaceuticals, INC. | $15.71 | 2023 | Inpefa |
| Alkermes, INC. | $13.79 | 2023 | Lybalvi |
| Esperion Therapeutics, INC. | $12.40 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.